000 | nab a22 7a 4500 | ||
---|---|---|---|
999 |
_c16900 _d16900 |
||
003 | PC16900 | ||
005 | 20220614125612.0 | ||
008 | 220614b xxu||||| |||| 00| 0 eng d | ||
040 | _cH12O | ||
041 | _aeng | ||
100 |
_9869 _aSan Juan Garrido, Rafael _eMedicina Interna |
||
100 |
_9263 _aFernández Ruiz, Mario _eMedicina Interna |
||
100 |
_9162 _aLópez Medrano, Francisco _eEnfermedades Infecciosas |
||
100 |
_9876 _aAguado García, José María _eEnfermedades Infecciosas |
||
245 | 0 | 0 |
_aCurrent preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. _h[artículo] |
260 |
_bClinical microbiology and infection, _c2015 |
||
300 | _a21(6):604.e1-9. | ||
500 | _aFormato Vancouver: San Juan R, Manuel O, Hirsch HH, Fernández Ruiz M, López Medrano F, Comoli P et al; ESGICH PTLD Survey Study Group; European Study Group of Infections in Compromised Hosts (ESGICH) from the European Society of Microbiology and Infectious Diseases (ESCMID). Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clin Microbiol Infect. 2015 Jun;21(6):604.e1-9. | ||
501 | _aPMID: 25686696 | ||
504 | _aContiene 39 referencias | ||
520 | _aThere is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients. | ||
710 |
_96 _aServicio de Medicina Interna |
||
856 |
_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16900.pdf _ySolicitar documento |
||
942 |
_2ddc _cART _n0 |